TB-500 Legal Status, FDA 503A Category, and Compounding Access

Momentum: TB-500 is on the FDA's July 2026 evaluation agenda

The TB-500 legal status is in motion. "TB-500 (free base)" and "TB-500 acetate" are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List." The same agenda also lists BPC-157, KPV, and MOTs-C.

That is the forward-leaning fact, and it deserves to be read precisely. A scheduled PCAC discussion is a step in FDA's evaluation — an advisory meeting where a substance under review is discussed. It is not a listing decision, not a reclassification, and not a change in current status. The committee advises; FDA decides separately, by rulemaking, and no outcome should be assumed or dated. What is true today is that access to compounded TB-500 is being actively examined, and the channel through which it could expand is open and on the calendar.

The current fact: TB-500 is in FDA 503A Category 2

As of today, the FDA lists the substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the agency's own entry establishes that TB-500 is the LKKTETQ fragment of thymosin beta-4. The FDA placed it in 503A "Category 2": bulk substances identified as potentially presenting significant safety risks. The placement took effect with the FDA's September 29, 2023 update to the list of substances nominated for use in 503A compounding, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information.

Two consequences follow from Category 2. First, as a Category 2 substance, TB-500 is not within the FDA's enforcement-discretion policy for 503A compounding — the policy that, for Category 1 substances, lets compounding proceed during evaluation does not extend to it. Second, TB-500 is not an FDA-approved drug; FDA approval of a finished medicine is a separate question from whether a bulk substance may be used in compounding, and the fragment has neither. (FDA, "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks," verified loading and containing this entry on 2026-05-29.)

How the 503A/503B framework works

Drug compounding in the United States runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, made pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA inspection.

A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet on a bulks list are evaluated through a public nomination process with input from the PCAC. Being discussed by the PCAC is a step in that evaluation, not a final listing decision — which is exactly the stage TB-500 occupies.

How legally compounded peptide access works

Set against that framework, the lawful access pathway is straightforward to describe in general terms — and it is general information here, not medical or legal advice, and not an offer to supply any substance.

A legally compounded medication is prepared only after a patient is evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter, who determines that a compounded preparation is clinically appropriate. If it is, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or for office and batch use sourced from an FDA-registered 503B outsourcing facility.

Telehealth functions as a front-end channel to that prescriber consultation — a route to evaluation and a prescription, not a separate legal status. It does not change which substances may be compounded. And that is the binding caveat for TB-500: a compounder may use a requested ingredient only if it is eligible under the 503A/503B bulk-substance rules, and an ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands. While TB-500 sits in Category 2, the eligibility step is where the pathway stops.

Banned in sport: WADA prohibition

Independent of the FDA question, TB-500 is prohibited in sport. It falls under the World Anti-Doping Agency's prohibited peptide and growth-factor and tissue-repair categories, banned both in and out of competition for the relevant classes. Anti-doping laboratories detect it by LC-MS assays validated in equine and human matrices — methods developed in part because TB-500 has been encountered as a designer substance in racehorses. WADA prohibition is a separate regime from FDA compounding status; a substance can be banned in sport regardless of its 503A standing.